Effectiveness of a genetic test panel designed for gynecological cancer: an exploratory study

Koichi Ida, Tsutomu Miyamoto, Shotaro Higuchi, Hodaka Takeuchi, Satoshi Yamada, Motoki Ono, Hiroshi Nishihara, Tanri Shiozawa

Research output: Contribution to journalArticle

Abstract

To increase diagnostic efficiency and cost-effectiveness, we performed an exploratory genetic test using a newly designed panel containing 28 actionable and druggable genes, alterations in which are frequently reported in gynecological cancers (TANRE-G, Targeted variants ANalysis RElated to Gynecological cancers). Samples consisted of the formalin-fixed, paraffin-embedded tissue of endometrial (4 cases), cervical (3 cases), and ovarian (4 cases) carcinomas. The sequencing procedure was performed using Ion PGM in our institute with related sequencing kits, and data were analyzed using ClinVar. The present system achieved more than 2500 reads in all tumor samples, and enabled a copy number variation analysis. Results showed that actionable and druggable mutations were detected in 82% (9/11) and 64% (7/11) of cases, respectively, which was similar to other commercially available genetic tests. The amplification of MYC and KRAS was also detected. The analysis cost for each sample was JPY 94,000 (USD 850). These results demonstrate the potential of the TANRE-G panel as an effective tool for examining genetic alterations in gynecological cancers.

Original languageEnglish
Article number62
JournalMedical Oncology
Volume36
Issue number7
DOIs
Publication statusPublished - 2019 Jul 1

Fingerprint

Neoplasms
Paraffin
Formaldehyde
Cost-Benefit Analysis
Ions
Carcinoma
Costs and Cost Analysis
Mutation
Genes

Keywords

  • Cervical carcinoma
  • Endometrial carcinoma
  • Gene panel
  • Genetic test
  • Ovarian carcinoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Ida, K., Miyamoto, T., Higuchi, S., Takeuchi, H., Yamada, S., Ono, M., ... Shiozawa, T. (2019). Effectiveness of a genetic test panel designed for gynecological cancer: an exploratory study. Medical Oncology, 36(7), [62]. https://doi.org/10.1007/s12032-019-1286-9

Effectiveness of a genetic test panel designed for gynecological cancer : an exploratory study. / Ida, Koichi; Miyamoto, Tsutomu; Higuchi, Shotaro; Takeuchi, Hodaka; Yamada, Satoshi; Ono, Motoki; Nishihara, Hiroshi; Shiozawa, Tanri.

In: Medical Oncology, Vol. 36, No. 7, 62, 01.07.2019.

Research output: Contribution to journalArticle

Ida, K, Miyamoto, T, Higuchi, S, Takeuchi, H, Yamada, S, Ono, M, Nishihara, H & Shiozawa, T 2019, 'Effectiveness of a genetic test panel designed for gynecological cancer: an exploratory study', Medical Oncology, vol. 36, no. 7, 62. https://doi.org/10.1007/s12032-019-1286-9
Ida, Koichi ; Miyamoto, Tsutomu ; Higuchi, Shotaro ; Takeuchi, Hodaka ; Yamada, Satoshi ; Ono, Motoki ; Nishihara, Hiroshi ; Shiozawa, Tanri. / Effectiveness of a genetic test panel designed for gynecological cancer : an exploratory study. In: Medical Oncology. 2019 ; Vol. 36, No. 7.
@article{f790b57bc0ef49ceb4ae8705328f0796,
title = "Effectiveness of a genetic test panel designed for gynecological cancer: an exploratory study",
abstract = "To increase diagnostic efficiency and cost-effectiveness, we performed an exploratory genetic test using a newly designed panel containing 28 actionable and druggable genes, alterations in which are frequently reported in gynecological cancers (TANRE-G, Targeted variants ANalysis RElated to Gynecological cancers). Samples consisted of the formalin-fixed, paraffin-embedded tissue of endometrial (4 cases), cervical (3 cases), and ovarian (4 cases) carcinomas. The sequencing procedure was performed using Ion PGM in our institute with related sequencing kits, and data were analyzed using ClinVar. The present system achieved more than 2500 reads in all tumor samples, and enabled a copy number variation analysis. Results showed that actionable and druggable mutations were detected in 82{\%} (9/11) and 64{\%} (7/11) of cases, respectively, which was similar to other commercially available genetic tests. The amplification of MYC and KRAS was also detected. The analysis cost for each sample was JPY 94,000 (USD 850). These results demonstrate the potential of the TANRE-G panel as an effective tool for examining genetic alterations in gynecological cancers.",
keywords = "Cervical carcinoma, Endometrial carcinoma, Gene panel, Genetic test, Ovarian carcinoma",
author = "Koichi Ida and Tsutomu Miyamoto and Shotaro Higuchi and Hodaka Takeuchi and Satoshi Yamada and Motoki Ono and Hiroshi Nishihara and Tanri Shiozawa",
year = "2019",
month = "7",
day = "1",
doi = "10.1007/s12032-019-1286-9",
language = "English",
volume = "36",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "7",

}

TY - JOUR

T1 - Effectiveness of a genetic test panel designed for gynecological cancer

T2 - an exploratory study

AU - Ida, Koichi

AU - Miyamoto, Tsutomu

AU - Higuchi, Shotaro

AU - Takeuchi, Hodaka

AU - Yamada, Satoshi

AU - Ono, Motoki

AU - Nishihara, Hiroshi

AU - Shiozawa, Tanri

PY - 2019/7/1

Y1 - 2019/7/1

N2 - To increase diagnostic efficiency and cost-effectiveness, we performed an exploratory genetic test using a newly designed panel containing 28 actionable and druggable genes, alterations in which are frequently reported in gynecological cancers (TANRE-G, Targeted variants ANalysis RElated to Gynecological cancers). Samples consisted of the formalin-fixed, paraffin-embedded tissue of endometrial (4 cases), cervical (3 cases), and ovarian (4 cases) carcinomas. The sequencing procedure was performed using Ion PGM in our institute with related sequencing kits, and data were analyzed using ClinVar. The present system achieved more than 2500 reads in all tumor samples, and enabled a copy number variation analysis. Results showed that actionable and druggable mutations were detected in 82% (9/11) and 64% (7/11) of cases, respectively, which was similar to other commercially available genetic tests. The amplification of MYC and KRAS was also detected. The analysis cost for each sample was JPY 94,000 (USD 850). These results demonstrate the potential of the TANRE-G panel as an effective tool for examining genetic alterations in gynecological cancers.

AB - To increase diagnostic efficiency and cost-effectiveness, we performed an exploratory genetic test using a newly designed panel containing 28 actionable and druggable genes, alterations in which are frequently reported in gynecological cancers (TANRE-G, Targeted variants ANalysis RElated to Gynecological cancers). Samples consisted of the formalin-fixed, paraffin-embedded tissue of endometrial (4 cases), cervical (3 cases), and ovarian (4 cases) carcinomas. The sequencing procedure was performed using Ion PGM in our institute with related sequencing kits, and data were analyzed using ClinVar. The present system achieved more than 2500 reads in all tumor samples, and enabled a copy number variation analysis. Results showed that actionable and druggable mutations were detected in 82% (9/11) and 64% (7/11) of cases, respectively, which was similar to other commercially available genetic tests. The amplification of MYC and KRAS was also detected. The analysis cost for each sample was JPY 94,000 (USD 850). These results demonstrate the potential of the TANRE-G panel as an effective tool for examining genetic alterations in gynecological cancers.

KW - Cervical carcinoma

KW - Endometrial carcinoma

KW - Gene panel

KW - Genetic test

KW - Ovarian carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85066463975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066463975&partnerID=8YFLogxK

U2 - 10.1007/s12032-019-1286-9

DO - 10.1007/s12032-019-1286-9

M3 - Article

C2 - 31139954

AN - SCOPUS:85066463975

VL - 36

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 7

M1 - 62

ER -